ZOMETA International Site for Healthcare Professionals Outside of the US
Resources
This is an international site for Zometa® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.
|
Print|
Text size:
Visit the ZOMETA Virtual Exhibit BoothTake a walk through the ZOMETA virtual exhibit booth to learn more about how ZOMETA reduces and delays skeletal-related events (SREs) in advanced cancers.1 Move your mouse below for more information |
|
|
|
| 1. Threat of Skeletal-Related Events | 4. Dose ZOMETA Every 3-4 Weeks |
| 2. ZOMETA Mechanism of Action | 5. Continue ZOMETA for up to 2 Years |
| 3. ZOMETA Efficacy | 6. ZOMETA is Generally Well Tolerated |
Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
About Novartis Oncology | Site Guide | Contact Us
Use of this website is subject to our Terms of Use and Privacy Statement
© Novartis AG.
Italiano
Français
Español
Deutsch
English
